

20. Huqun, Ishikawa R, Zhang J, Miyazawa H, Goto Y, Shimizu Y, Hagiwara K, Koyama N. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. *Cancer*. 2012;118(6):1599-606.
21. Goto K, Satouchi M, Ishii G, Nishio K, Hagiwara K, Mitsudomi T, Whiteley J, Donald E, McCormack R, Todo T. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. *Ann Oncol*. 2012;23:2914-9.

磯部 宏 (研究分担者)

1. Yokouchi H, Kanazawa K, Ishida T, Oizumi S, Shinagawa N, Sukoh N, Harada M, Ogura S, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M. Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review. *Molecular and Clinical Oncology*. 2014;2(5):744-50.
2. Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma A, Hagiwara K, Kobayashi K. Effectiveness of Gefitinib against Non-Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2014;9(2):189-94.
3. Kanazawa K, Yokouchi H, Wang X, Ishida T, Fujita Y, Fujiuchi S, Harada T, Harada M, Takamura K, Oizumi S, Kinoshita I, Katsuura Y, Honjo O, Kojima T, Dosaka-Akita H, Isobe H, Munakata M, Nishimura M, Hokkaido Lung Cancer Clinical Study G. Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902. *Cancer Chemotherapy and Pharmacology*. 2014;74(6):1149-57.
4. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). *Ann Oncol*. 2013;24(1):54-9.
5. Harada T, Oizumi S, Ito K, Takamura K, Kikuchi E, Kuda T, Sugawara S, Suzuki A, Maemondo M, Fujita Y, Kinoshita I, Inoue A, Hommura F, Katsuura Y, Dosaka-Akita H, Isobe H, Nishimura M, Hokkaido Lung Cancer Clinical Study G. A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901. *Oncologist*. 2013;18(4):439-45.
6. Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, Fujita Y, Gemma A, Yamashita Y, Ueno T, Takeuchi K, Choi YL, Miyazawa H, Tanaka T, Hagiwara K, Mano H. A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non-Small Cell Lung Cancer. *Clin Cancer Res*. 2012;18(20):5682-9.
7. Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial. *Oncologist*. 2012;17(6):863-70.

8. Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, Gemma A. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2012;7(9):1417-22.

弦間 昭彦 (研究分担者)

1. Iijima Y, Seike M, Noro R, Ibi T, Takeuchi S, Mikami I, Koizumi K, Usuda J, Gemma A. Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma. *International Journal of Oncology*. 2015;46(2):505-12.
2. Yoshizawa K, Mukai HY, Miyazawa M, Miyao M, Ogawa Y, Ohyashiki K, Katoh T, Kusumoto M, Gemma A, Sakai F, Sugiyama Y, Hatake K, Fukuda Y, Kudoh S. Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization. *Cancer Sci*. 2014;105(2):195-201.
3. Yamamoto K, Seike M, Takeuchi S, Soeno C, Miyanaga A, Noro R, Minegishi Y, Kubota K, Gemma A. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma. *Oncology Reports*. 2014;32(6):2365-72.
4. Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma A, Hagiwara K, Kobayashi K. Effectiveness of Gefitinib against Non-Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2014;9(2):189-94.
5. Ueyama M, Chikamatsu K, Aono A, Murase Y, Kuse N, Morimoto K, Okumura M, Yoshiyama T, Ogata H, Yoshimori K, Kudoh S, Azuma A, Gemma A, Mitarai S. Sub-speciation of Mycobacterium tuberculosis complex from tuberculosis patients in Japan. *Tuberculosis*. 2014;94(1):15-9.
6. Tanaka Y, Hino M, Mizuno K, Gemma A. Assessment of the relationship between right ventricular function and the severity of obstructive sleep-disordered breathing. *The Clinical Respiratory Journal*.. 2014;8(2):145-51.
7. Takiguchi Y, Iwasawa S, Minato K, Miura Y, Gemma A, Noro R, Yoshimori K, Shingyoji M, Hino M, Ando M, Okamoto H. Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naive patients with advanced non-squamous non-small cell lung cancer. *International Journal of Clinical Oncology*. 2014.
8. Takeuchi S, Seike M, Noro R, Soeno C, Sugano T, Zou F, Uesaka H, Nishijima N, Matsumoto M, Minegishi Y, Kubota K, Gemma A. Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed. *International Journal of Oncology*. 2014;44(6):1886-94.
9. Satoh T, Gemma A, Kudoh S, Sakai F, Yamaguchi K, Watanabe T, Ishiguro M, Inoshiri S, Izawa M, Sugihara K, Sakata Y. Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registry. *Japanese Journal of Clinical*

Oncology. 2014;44(11):1032-9.

10. Satoh E, Tagami T, Watanabe A, Matsumoto G, Suzuki G, Onda H, Fuse A, Gemma A, Yokota H. Association between Serum Lactate Levels and Early Neurogenic Pulmonary Edema after Nontraumatic Subarachnoid Hemorrhage. 2014;81(5):305-12.
11. Morimoto K, Yoshiyama T, Kurashima A, Sasaki Y, Hoshino Y, Yoshimori K, Ogata H, Gemma A, Kudoh S, Shiraishi Y. Nutritional indicators are correlated with the radiological severity score in patients with Mycobacterium avium complex pulmonary disease: a cross-sectional study. Internal Medicine. 2014;53(5):397-401.
12. Morimoto K, Iwai K, Uchimura K, Okumura M, Yoshiyama T, Yoshimori K, Ogata H, Kurashima A, Gemma A, Kudoh S. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Annals of the American Thoracic Society. 2014;11(1):1-8.
13. Minegishi Y, Kokuho N, Miura Y, Matsumoto M, Miyanaga A, Noro R, Saito Y, Seike M, Kubota K, Azuma A, Kida K, Gemma A. Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema. Lung Cancer. 2014;85(2):258-63.
14. Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study G. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903). Lung Cancer. 2014;86(2):195-200.
15. Maemondo M, Inoue A, Sugawara S, Harada T, Minegishi Y, Usui K, Miwa K, Morikawa N, Kambe M, Ube K, Watanabe K, Ishimoto O, Sakakibara T, Gemma A, Nukiwa T. Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801. Oncologist. 2014;19(4):352-3.
16. Kokuho N, Ishii T, Kamio K, Hayashi H, Kurahara M, Hattori K, Motegi T, Azuma A, Gemma A, Kida K. Diagnostic Values For Club Cell Secretory Protein (CC16) in Serum of Patients of Combined Pulmonary Fibrosis and Emphysema. COPD. 2014.
17. Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K, Gemma A. MiR-134/487b/655 cluster regulates TGF-beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Molecular Cancer Therapeutics. 2014;13(2):444-53.
18. Ishii T, Motegi T, Kamio K, Gemma A, Kida K. Association of group component genetic variations in COPD and COPD exacerbation in a Japanese population. Respiriology. 2014;19(4):590-5.
19. Ishii T, Gemma A, Kida K. Senescence is involved in the pathogenesis of chronic obstructive pulmonary disease through effects on telomeres and the anti-aging molecule fibroblast growth factor 23. Geriatrics & Gerontology International. 2014.

20. Inomata M, Kamio K, Azuma A, Matsuda K, Kokuho N, Miura Y, Hayashi H, Nei T, Fujita K, Saito Y, Gemma A. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. *Respiratory Research*. 2014;15:16.
21. Inomata M, Ikushima S, Awano N, Kondoh K, Satake K, Masuo M, Kusunoki Y, Moriya A, Kamiya H, Ando T, Yanagawa N, Kumasaka T, Ogura T, Sakai F, Azuma A, Gemma A, Takemura T. An autopsy study of combined pulmonary fibrosis and emphysema: correlations among clinical, radiological, and pathological features. *BMC Pulmonary Medicine*. 2014;14:104.
22. Hirakawa A, Yonemori K, Kuwatsuka Y, Kodaira M, Yamamoto H, Yunokawa M, Hamada A, Shimizu C, Tamura K, Gemma A, Fujiwara Y. A descriptive analysis of post-chemotherapy development of interstitial lung disease using spontaneous reporting data in Japan. *Current Drug Safety*. 2014;9(3):220-6.
23. Gemma A, Kudoh S, Ando M, Ohe Y, Nakagawa K, Johkoh T, Yamazaki N, Arakawa H, Inoue Y, Ebina M, Kusumoto M, Kuwano K, Sakai F, Taniguchi H, Fukuda Y, Seki A, Ishii T, Fukuoka M. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. *Cancer Sci*. 2014;105(12):1584-90.
24. Boku N, Sugihara K, Kitagawa Y, Hatake K, Gemma A, Yamazaki N, Muro K, Hamaguchi T, Yoshino T, Yana I, Ueno H, Ohtsu A. Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients. *Japanese Journal of Clinical Oncology*. 2014;44(3):214-23.
25. Angata T, Ishii T, Gao C, Ohtsubo K, Kitazume S, Gemma A, Kida K, Taniguchi N. Association of serum interleukin-27 with the exacerbation of chronic obstructive pulmonary disease. *Physiological Reports*. 2014;2(7).
26. Tanaka Y, Hino M, Mizuno K, Gemma A. Evaluation of right ventricular function in patients with COPD. *Respiratory Care*. 2013;58(5):816-23.
27. Shiozawa T, Tadokoro J, Fujiki T, Fujino K, Kakihata K, Masatani S, Morita S, Gemma A, Boku N. Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. *Japanese Journal of Clinical Oncology*. 2013;43(5):483-91.
28. Saito Y, Nagayama M, Miura Y, Ogushi S, Suzuki Y, Noro R, Minegishi Y, Kimura G, Kondo Y, Gemma A. A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma. *Japanese Journal of Clinical Oncology*. 2013;43(5):559-62.
29. Saito Y, Kunugi S, Suzuki Y, Narita K, Miura Y, Minegishi Y, Kimura G, Kondo Y, Azuma A, Fukuda Y, Gemma A. Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy. *Internal Medicine*. 2013;52(2):263-7.
30. Noro R, Yoshimura A, Yamamoto K, Miyanaga A, Mizutani H, Minegishi Y, Seike M, Kubota K, Kosaihiro S, Hino M, Ando M, Nomura K, Okano T, Kobayashi K, Uematsu K, Gemma A, East Japan Chesters G. Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus

cisplatin for extensive-stage small cell lung cancer. *Anticancer Research*. 2013;33(3):1117-23.

31. Noro R, Honda K, Tsuta K, Ishii G, Maeshima AM, Miura N, Furuta K, Shibata T, Tsuda H, Ochiai A, Sakuma T, Nishijima N, Gemma A, Asamura H, Nagai K, Yamada T. Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification. *Ann Oncol*. 2013;24(10):2594-600.
32. Narita K, Noro R, Seike M, Matsumoto M, Fujita K, Matsumura J, Takahashi M, Kawamoto M, Gemma A. Successful treatment of histiocytic sarcoma and concurrent HIV infection using a combination of CHOP and antiretroviral therapy. *Internal Medicine*. 2013;52(24):2805-9.
33. Motegi T, Jones RC, Ishii T, Hattori K, Kusunoki Y, Furutate R, Yamada K, Gemma A, Kida K. A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations. *International Journal of Chronic Obstructive Pulmonary Disease*. 2013;8:259-71.
34. Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihiro S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, Tsuchiya S, Hagiwara K, Soda M, Takeuchi K, Yamamoto N, Mano H, Ishikawa Y, Gemma A. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. *BMC Cancer*. 2013;13:262.
35. Miyanaga A, Honda K, Tsuta K, Masuda M, Yamaguchi U, Fujii G, Miyamoto A, Shinagawa S, Miura N, Tsuda H, Sakuma T, Asamura H, Gemma A, Yamada T. Diagnostic and prognostic significance of the alternatively spliced ACTN4 variant in high-grade neuroendocrine pulmonary tumours. *Ann Oncol*. 2013;24(1):84-90.
36. Kuse N, Abe S, Hayashi H, Kamio K, Saito Y, Azuma A, Kudoh S, Kunugi S, Fukuda Y, Setoguchi Y, Gemma A. Familial interstitial pneumonia in an adolescent boy with surfactant protein C gene (Y104H) mutation. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders. 2013;30(1):73-7.
37. Kitamura K, Kubota K, Ando M, Takahashi S, Nishijima N, Sugano T, Toyokawa M, Miwa K, Kosaihiro S, Noro R, Minegishi Y, Seike M, Yoshimura A, Gemma A. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. *Cancer Chemotherapy and Pharmacology*. 2013;71(2):457-61.
38. Kamio K, Ishii T, Motegi T, Hattori K, Kusunoki Y, Azuma A, Gemma A, Kida K. Decreased serum transforming growth factor-beta1 concentration with aging is associated with the severity of emphysema in chronic obstructive pulmonary disease. *Geriatrics & Gerontology International*. 2013;13(4):1069-75.
39. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). *Ann Oncol*. 2013;24(1):54-9.
40. Horiuchi-Yamamoto Y, Gemma A, Taniguchi H, Inoue Y, Sakai F, Johkoh T, Fujimoto K, Kudoh S. Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan.

41. Angata T, Ishii T, Motegi T, Oka R, Taylor RE, Soto PC, Chang YC, Secundino I, Gao CX, Ohtsubo K, Kitazume S, Nizet V, Varki A, Gemma A, Kida K, Taniguchi N. Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation. *Cellular and Molecular Life Sciences : CMLS*. 2013;70(17):3199-210.
42. Yoshimura A, Noro R, Miyanaga A, Mizutani H, Kosaihiro S, Minegishi Y, Seike M, Hino M, Ando M, Nomura K, Okano T, Kobayashi K, Gemma A, East Japan Chesters G. Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer. *Anticancer Research*. 2012;32(10):4473-8.
43. Usuki J, Matsuda K, Azuma A, Kudoh S, Gemma A. Sequential analysis of myofibroblast differentiation and transforming growth factor-beta1/Smad pathway activation in murine pulmonary fibrosis. *Journal of Nippon Medical School*. 2012;79(1):46-59.
44. Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, Fujita Y, Gemma A, Yamashita Y, Ueno T, Takeuchi K, Choi YL, Miyazawa H, Tanaka T, Hagiwara K, Mano H. A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non-Small Cell Lung Cancer. *Clin Cancer Res*. 2012;18(20):5682-9.
45. Shimokawa T, Seike M, Soeno C, Uesaka H, Miyanaga A, Mizutani H, Kitamura K, Minegishi Y, Noro R, Okano T, Yoshimura A, Gemma A. Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules. *British Journal of Cancer*. 2012;106(5):867-75.
46. Saito Y, Gemma A. Current status of DILD in molecular targeted therapies. *International Journal of Clinical Oncology*. 2012;17(6):534-41.
47. Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial. *Oncologist*. 2012;17(6):863-70.
48. Motegi T, Yamada K, Ishii T, Gemma A, Kida K. Long-term management of chronic obstructive pulmonary disease: a survey of collaboration among physicians involved in pulmonary rehabilitation in Japan. *Respiratory Investigation*. 2012;50(3):98-103.
49. Morimoto K, Yoshiyama T, Okumura M, Hoshino Y, Yoshimori K, Ogata H, Kurashima A, Gemma A, Kudoh S. Multidrug-resistant tuberculosis with a history of nontuberculous Mycobacteriosis: a brief report of two cases. *Internal Medicine*. 2012;51(24):3435-7.
50. Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, Gemma A. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2012;7(9):1417-22.

51. Kashiwada T, Kikuchi K, Abe S, Kato H, Hayashi H, Morimoto T, Kamio K, Usuki J, Takeda S, Tanaka K, Imanishi K, Yagi J, Azuma A, Gemma A. Staphylococcal enterotoxin B toxic shock syndrome induced by community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA). *Internal Medicine*. 2012;51(21):3085-8.
52. Kamio K, Yoshida T, Gao C, Ishii T, Ota F, Motegi T, Kobayashi S, Fujinawa R, Ohtsubo K, Kitazume S, Angata T, Azuma A, Gemma A, Nishimura M, Betsuyaku T, Kida K, Taniguchi N. alpha1,6-Fucosyltransferase (Fut8) is implicated in vulnerability to elastase-induced emphysema in mice and a possible non-invasive predictive marker for disease progression and exacerbations in chronic obstructive pulmonary disease (COPD). *Biochemical and Biophysical Research Communications*. 2012;424(1):112-7.
53. Ishii T, Hagiwara K, Kamio K, Ikeda S, Arai T, Mieno MN, Kumasaka T, Muramatsu M, Sawabe M, Gemma A, Kida K. Involvement of surfactant protein D in emphysema revealed by genetic association study. *Eur J Hum Genet*. 2012;20(2):230-5.
54. Ishii T, Hagiwara K, Ikeda S, Arai T, Mieno MN, Kumasaka T, Muramatsu M, Sawabe M, Gemma A, Kida K. Association Between Genetic Variations In Surfactant Protein D and Emphysema, Interstitial Pneumonia, and Lung Cancer in a Japanese Population. *COPD*. 2012;9:409-16.
55. Hayashi H, Saito Y, Kokuho N, Morimoto T, Kobayashi K, Tanaka T, Abe S, Fujita K, Azuma A, Gemma A. Fatal pneumonia associated with temozolomide therapy in patients with malignant glioma. *Japanese Journal of Clinical Oncology*. 2012;42(7):632-6.
56. Cao M, Seike M, Soeno C, Mizutani H, Kitamura K, Minegishi Y, Noro R, Yoshimura A, Cai L, Gemma A. MiR-23a regulates TGF-beta-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. *International Journal of Oncology*. 2012;41(3):869-75.

石井 芳樹 (研究分担者)

1. Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma A, Hagiwara K, Kobayashi K. Effectiveness of Gefitinib against Non-Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2014;9(2):189-94.
2. Shimizu Y, Takise A, Morita H, Hosomi Y, Kasahara N, Kawata T, Horie T, Ishii Y, Yamada M. Serum glycopeptidolipid core IgA antibody levels in patients with chest computed tomography features of mycobacterium aviumintracellulare complex pulmonary disease. *Journal of Biological Regulators and Homeostatic Agents*. 2014;28(3):399-405.
3. Shimizu Y, Shimoyama Y, Kawada A, Kusano M, Hosomi Y, Sekiguchi M, Kawata T, Horie T, Ishii Y, Yamada M, Dobashi K, Takise A. Gastrointestinal symptoms in idiopathic pulmonary fibrosis patients treated with pirfenidone and herbal medicine. *Journal of Biological Regulators and Homeostatic Agents*. 2014;28(3):433-42.
4. Shimizu Y, Kamiyoshihara M, Okajo J, Ishii Y, Takise A. Tracheobronchial stenosis evaluated by inspiratory and expiratory three-dimensional computed tomography and impulse oscillation with three-dimensional

color imaging in a patient with relapsing polycondritis. *Journal of Biological Regulators and Homeostatic Agents*. 2014;28(2):325-31.

5. Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study G. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903). *Lung cancer*. 2014;86(2):195-200.
6. Hayashi Y, Hirata H, Watanabe M, Yoshida N, Yokoyama T, Murayama Y, Sugiyama K, Arima M, Fukushima Y, Fukuda T, Ishii Y. Epidemiologic investigation of hornet and paper wasp stings in forest workers and electrical facility field workers in Japan. *Allergology international : official journal of the Japanese Society of Allergology*. 2014;63(1):21-6.
7. Hayashi Y, Hirata H, Watanabe M, Yoshida N, Yokoyama T, Kakuta T, Murayama Y, Sugiyama K, Arima M, Fukushima Y, Fukuda T, Ishii Y. Usefulness of specific-IgG4 to Hymenoptera venom in the natural history of hymenoptera stings. *Journal of Investigational Allergology & Clinical Immunology*. 2014;24(3):192-4.
8. Hayashi Y, Ishii Y, Hata-Suzuki M, Arai R, Chibana K, Takemasa A, Fukuda T. Comparative analysis of circulating dendritic cell subsets in patients with atopic diseases and sarcoidosis. *Respiratory Research*. 2013;14:29.
9. Takemasa A, Ishii Y, Fukuda T. A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice. *The European Respiratory Journal*. 2012;40(6):1475-82.

久保田 馨 (研究分担者)

1. Yamamoto K, Seike M, Takeuchi S, Soeno C, Miyanaga A, Noro R, Minegishi Y, Kubota K, Gemma A. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma. *Oncology Reports*. 2014;32(6):2365-72.
2. Takeuchi S, Seike M, Noro R, Soeno C, Sugano T, Zou F, Uesaka H, Nishijima N, Matsumoto M, Minegishi Y, Kubota K, Gemma A. Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed. *International Journal of Oncology*. 2014;44(6):1886-94.
3. Niho S, Nokihara H, Nihei K, Akimoto T, Sumi M, Ito Y, Yoh K, Goto K, Ohmatsu H, Horinouchi H, Yamamoto N, Sekine I, Kubota K, Ohe Y, Tamura T. Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin in Japanese Patients With Locally Advanced Nonsquamous Non-Small Cell Lung Cancer: A Post Hoc Analysis of Survival and Recurrent Sites. *American Journal of Clinical Oncology*. 2014.
4. Minegishi Y, Kokuho N, Miura Y, Matsumoto M, Miyanaga A, Noro R, Saito Y, Seike M, Kubota K, Azuma A, Kida K, Gemma A. Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema. *Lung Cancer*. 2014;85(2):258-63.
5. Kubota K, Ichinose Y, Scagliotti G, Spigel D, Kim JH, Shinkai T, Takeda K, Kim SW, Hsia TC, Li RK, Tiangco BJ, Yau S, Lim WT, Yao B, Hei YJ, Park K. Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis. *Ann*

6. Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, Yokoyama A, Imamura F, Takeda K, Negoro S, Harada M, Okamoto H, Yamamoto N, Shinkai T, Sakai H, Matsui K, Nakagawa K, Shibata T, Saijo N, Tamura T, Japan Clinical Oncology G. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. *The Lancet Oncology*. 2014;15(1):106-13.
7. Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K, Gemma A. MiR-134/487b/655 cluster regulates TGF-beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. *Molecular Cancer Therapeutics*. 2014;13(2):444-53.
8. Kenmotsu H, Niho S, Ito T, Ishikawa Y, Noguchi M, Tada H, Sekine I, Watanabe S, Yoshimura M, Yamamoto N, Oshita F, Kubota K, Nagai K. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer). *Lung Cancer*. 2014;84(3):254-8.
9. Fujimori M, Shirai Y, Asai M, Kubota K, Katsumata N, Uchitomi Y. Effect of communication skills training program for oncologists based on patient preferences for communication when receiving bad news: a randomized controlled trial. *Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology*. 2014;32(20):2166-72.
10. Fujimori M, Shirai Y, Asai M, Akizuki N, Katsumata N, Kubota K, Uchitomi Y. Development and preliminary evaluation of communication skills training program for oncologists based on patient preferences for communicating bad news. *Palliative & Supportive Care*. 2014;12(5):379-86.
11. Sekine I, Segawa Y, Kubota K, Saeki T. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. *Cancer Sci*. 2013;104(6):711-7.
12. Noro R, Yoshimura A, Yamamoto K, Miyanaga A, Mizutani H, Minegishi Y, Seike M, Kubota K, Kosaihiro S, Hino M, Ando M, Nomura K, Okano T, Kobayashi K, Uematsu K, Gemma A, East Japan Chesters G. Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer. *Anticancer Research*. 2013;33(3):1117-23.
13. Niho S, Kubota K, Nihei K, Sekine I, Sumi M, Sekiguchi R, Funai J, Enatsu S, Ohe Y, Tamura T. Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer. *Clinical Lung Cancer*. 2013;14(1):62-9.
14. Kuroda Y, Sekine I, Sumi M, Sekii S, Takahashi K, Inaba K, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Murakami N, Morota M, Mayahara H, Ito Y, Tamura T, Nemoto K, Itami J. Acute radiation esophagitis caused by high-dose involved field radiotherapy with concurrent cisplatin and vinorelbine for stage III non-small cell lung cancer. *Technology in Cancer Research & Treatment*. 2013;12(4):333-9.

15. Kitamura K, Kubota K, Ando M, Takahashi S, Nishijima N, Sugano T, Toyokawa M, Miwa K, Kosaihiro S, Noro R, Minegishi Y, Seike M, Yoshimura A, Gemma A. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. *Cancer Chemotherapy and Pharmacology*. 2013;71(2):457-61.
16. Kawahara M, Atagi S, Komuta K, Yoshioka H, Kawasaki M, Fujita Y, Yonei T, Ogushi F, Kubota K, Nogami N, Tsuchiya M, Shibata K, Tomizawa Y, Minato K, Fukuoka K, Asami K, Yamanaka T, Japan Multinational Trial O. Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer. *Anticancer Research*. 2013;33(10):4631-7.
17. Horinouchi H, Kubota K, Itani H, Taniyama TK, Nakamichi S, Wakui H, Kanda S, Nokihara H, Yamamoto N, Sekine I, Tamura T. Short hydration in chemotherapy containing cisplatin (≥ 75 mg/m²) for patients with lung cancer: a prospective study. *Japanese Journal of Clinical Oncology*. 2013;43(11):1105-9.
18. Yoh K, Kubota K, Ohmatsu H, Goto K, Niho S, Ohe Y. Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases. *Anticancer Research*. 2012;32(9):4131-5.
19. Sekine I, Sumi M, Ito Y, Horinouchi H, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Kubota K, Tamura T. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer. *International Journal of Radiation Oncology, Biology, Physics*. 2012;82(2):953-9.
20. Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. *Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology*. 2012;30(23):2829-36.
21. Minami-Shimmyo Y, Ohe Y, Yamamoto S, Sumi M, Nokihara H, Horinouchi H, Yamamoto N, Sekine I, Kubota K, Tamura T. Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2012;7(1):177-82.
22. Asahina H, Sekine I, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Tamura T. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. *Clinical Lung Cancer*. 2012;13(1):39-43.

小林 国彦 (研究分担者)

1. Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma A, Hagiwara K, Kobayashi K. Effectiveness of Gefitinib against Non-Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2014;9(2):189-94.

2. Saito T, Fujii M, Saito S, Shimada K, Fujiwara K, Kobayashi K. Pharmacokinetics of a new fentanyl tape with a novel delivery system of transdermal matrix patches in patients with cancer pain. *Oncology*. 2014;86(1):10-5.
3. Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study G. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903). *Lung cancer*. 2014;86(2):195-200.
4. Kotajima F, Kobayashi K, Sakaguchi H, Nemoto M. Lung cancer patients frequently visit the emergency room for cancer-related and -unrelated issues. *Molecular and Clinical Oncology*. 2014;2(2):322-6.
5. Kawano Y, Okamoto I, Fukuda H, Ohe Y, Nakamura S, Nakagawa K, Hotta K, Kiura K, Takiguchi Y, Saka H, Okamoto H, Takayama K, Semba H, Kobayashi K, Kenmotsu H, Tsuboi M, Yamamoto N, Nukiwa T, Nakanishi Y. Current status and future perspectives of cooperative study groups for lung cancer in Japan. *Respiratory Investigation*. 2014;52(6):339-47.
6. Inoue A, Sugawara S, Harada M, Kobayashi K, Kozuki T, Kuyama S, Maemondo M, Asahina H, Hisamoto A, Nakagawa T, Hotta K, Nukiwa T. Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2014;9(12):1805-9.
7. Hirama T, Minezaki S, Yamaguchi T, Kishi E, Kodama K, Egashira H, Kobayashi K, Nagata M, Ishii T, Nemoto M, Tanaka M, Fukunaga K, Kanazawa M, Hagiwara K. HIRA-TAN: a real-time PCR-based system for the rapid identification of causative agents in pneumonia. *Respiratory Medicine*. 2014;108(2):395-404.
8. Vivat B, Young T, Efficace F, Sigurdadottir V, Arraras JJ, Asgeirsdottir GH, Bredart A, Costantini A, Kobayashi K, Singer S, Group EQoL. Cross-cultural development of the EORTC QLQ-SWB36: a stand-alone measure of spiritual wellbeing for palliative care patients with cancer. *Palliative Medicine*. 2013;27(5):457-69.
9. Noro R, Yoshimura A, Yamamoto K, Miyanaga A, Mizutani H, Minegishi Y, Seike M, Kubota K, Kosaihiro S, Hino M, Ando M, Nomura K, Okano T, Kobayashi K, Uematsu K, Gemma A, East Japan Chesters G. Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer. *Anticancer Research*. 2013;33(3):1117-23.
10. Kobayashi K, Hagiwara K. Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). *Target Oncol*. 2013;8(1):27-33.
11. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). *Ann Oncol*. 2013;24(1):54-9.

12. Hagiwara K, Kobayashi K. Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancer. *Cancer Sci.* 2013;104(3):291-7.
13. Akamatsu H, Inoue A, Mitsudomi T, Kobayashi K, Nakagawa K, Mori K, Nukiwa T, Nakanishi Y, Yamamoto N. Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405). *Japanese Journal of Clinical Oncology.* 2013;43(6):664-8.
14. Yoshimura A, Noro R, Miyanaga A, Mizutani H, Kosaihiro S, Minegishi Y, Seike M, Hino M, Ando M, Nomura K, Okano T, Kobayashi K, Gemma A, East Japan Chesters G. Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer. *Anticancer Research.* 2012;32(10):4473-8.
15. Yamada N, Oizumi S, Asahina H, Shinagawa N, Kikuchi E, Kikuchi J, Sakakibara-Konishi J, Tanaka T, Kobayashi K, Hagiwara K, Nishimura M. The Peptide nucleic Acid-locked nucleic Acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations in bronchoscopic cytological specimens of non-small cell lung cancer. *Oncology.* 2012;82(6):341-6.
16. Tada Y, Okano T, Kaga A, Yamazaki S, Kawada S, Ishida M, Kobayashi K, Onishi H. Dissociative stupor mimicking consciousness disorder in an advanced lung cancer patient. *Japanese Journal of Clinical Oncology.* 2012;42(6):548-51.
17. Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial. *Oncologist.* 2012;17(6):863-70.
18. Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, Gemma A. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.* 2012;7(9):1417-22.
19. Komiyama K, Kobayashi K, Minezaki S, Kotajima F, Sutani A, Kasai T, Mori K, Hoshi E, Takayanagi N, Koyama S, Eguchi K, Nakayama M, Kikuchi K, Kanto Respiratory Disease Study G. Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601). *British Journal of Cancer.* 2012;107(9):1474-80.
20. Hayashi H, Saito Y, Kokuho N, Morimoto T, Kobayashi K, Tanaka T, Abe S, Fujita K, Azuma A, Gemma A. Fatal pneumonia associated with temozolomide therapy in patients with malignant glioma. *Japanese Journal of Clinical Oncology.* 2012;42(7):632-6.
21. Gotay C, Orimoto T, Kobayashi K. Content Validity and Feasibility of the Care Notebook to Assess Cancer-Related Quality of Life in Hawaii. *Ann Cancer Res Ther.* 2012;20:68-73.

22. Ebara T, Kawamura H, Kaminuma T, Okamoto M, Yoshida D, Okubo Y, Takahashi T, Kobayashi K, Sakaguchi H, Ando Y, Nakano T. Hemithoracic intensity-modulated radiotherapy using helical tomotherapy for patients after extrapleural pneumonectomy for malignant pleural mesothelioma. *Journal of radiation research*. 2012;53(2):288-94.

西條 康夫（研究分担者）

1. Zhou Q, Ye X, Sun R, Matsumoto Y, Moriyama M, Asano Y, Ajioka Y, Saijo Y. Differentiation of mouse induced pluripotent stem cells into alveolar epithelial cells in vitro for use in vivo. *Stem Cells Translational Medicine*. 2014;3(6):675-85.
2. Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study G. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903). *Lung Cancer*. 2014;86(2):195-200.
3. Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, Yokoyama A, Imamura F, Takeda K, Negoro S, Harada M, Okamoto H, Yamamoto N, Shinkai T, Sakai H, Matsui K, Nakagawa K, Shibata T, Saijo N, Tamura T, Japan Clinical Oncology G. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. *The Lancet Oncology*. 2014;15(1):106-13.
4. Sun R, Zhou Q, Ye X, Takahata T, Ishiguro A, Kijima H, Nukiwa T, Saijo Y. A change in the number of CCSP(pos)/SPC(pos) cells in mouse lung during development, growth, and repair. *Respiratory Investigation*. 2013;51(4):229-40.
5. Sugawara S, Maemondo M, Tachihara M, Inoue A, Ishimoto O, Sakakibara T, Usui K, Watanabe H, Matsubara N, Watanabe K, Kanazawa K, Ishida T, Saijo Y, Nukiwa T, North Japan Lung Cancer Study G. Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601. *Lung Cancer*. 2013;81(1):91-6.
6. Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, Saijo Y, Sakai F, Sugiyama Y, Tatsumi K, Dohi M, Tokuda H, Hashimoto S, Hattori N, Hanaoka M, Fukuda Y, Japanese Respiratory Society Committee for formulation of Consensus statement for the d, treatment of drug-induced lung i. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. *Respiratory Investigation*. 2013;51(4):260-77.
7. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). *Ann Oncol*. 2013;24(1):54-9.

8. Takahata T, Itoh J, Satoh T, Ishiguro A, Matsumoto Y, Tanaka S, Saitoh S, Tohno H, Fukuda S, Saijo Y, Sakata Y. Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study. *Oncology Letters*. 2012;3(1):89-93.
9. Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial. *Oncologist*. 2012;17(6):863-70.
10. Ohkouchi S, Block GJ, Katsha AM, Kanehira M, Ebina M, Kikuchi T, Saijo Y, Nukiwa T, Prockop DJ. Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC1. *Molecular therapy : the Journal of the American Society of Gene Therapy*. 2012;20(2):417-23.
11. Hanada N, Takahata T, Zhou Q, Ye X, Sun R, Itoh J, Ishiguro A, Kijima H, Mimura J, Itoh K, Fukuda S, Saijo Y. Methylation of the KEAP1 gene promoter region in human colorectal cancer. *BMC Cancer*. 2012;12:66.

岡崎 康司（研究分担者）

1. Uehara N, Mori M, Tokuzawa Y, Mizuno Y, Tamaru S, Kohda M, Moriyama Y, Nakachi Y, Matoba N, Sakai T, Yamazaki T, Harashima H, Murayama K, Hattori K, Hayashi J, Yamagata T, Fujita Y, Ito M, Tanaka M, Nibu K, Ohtake A, Okazaki Y. New MT-ND6 and NDUFA1 mutations in mitochondrial respiratory chain disorders. *Annals of Clinical and Translational Neurology*. 2014;1(5):361-9.
2. Tsuchihashi T, Mori K, Horie-Inoue K, Okazaki Y, Awata T, Inoue S, Yoneya S. Prognostic phenotypic and genotypic factors associated with photodynamic therapy response in patients with age-related macular degeneration. *Clinical Ophthalmology*. 2014;8:2471-8.
3. Ohtake A, Murayama K, Mori M, Harashima H, Yamazaki T, Tamaru S, Yamashita Y, Kishita Y, Nakachi Y, Kohda M, Tokuzawa Y, Mizuno Y, Moriyama Y, Kato H, Okazaki Y. Diagnosis and molecular basis of mitochondrial respiratory chain disorders: exome sequencing for disease gene identification. *Biochimica et biophysica acta*. 2014;1840(4):1355-9.
4. Muramatsu M, Okuda A, Okazaki Y. Genomic aspects of common diseases. *Biochemical and Biophysical Research Communications*. 2014;452(2):211-2.
5. Montassir H, Maegaki Y, Murayama K, Yamazaki T, Kohda M, Ohtake A, Iwasa H, Yatsuka Y, Okazaki Y, Sugiura C, Nagata I, Toyoshima M, Saito Y, Itoh M, Nishino I, Ohno K. Myocerebrohepatopathy spectrum disorder due to POLG mutations: A Clinicopathological report. *Brain & Development*. 2014.
6. Kopajtich R, Nicholls TJ, Rorbach J, Metodiev MD, Freisinger P, Mandel H, Vanlander A, Ghezzi D, Carrozzo R, Taylor RW, Marquard K, Murayama K, Wieland T, Schwarzmayr T, Mayr JA, Pearce SF, Powell CA, Saada A, Ohtake A, Invernizzi F, Lamantea E, Sommerville EW, Pyle A, Chinnery PF, Crushell E, Okazaki Y, Kohda M, Kishita Y, Tokuzawa Y, Assouline Z, Rio M, Feillet F, Mousson de Camaret B, Chretien D, Munnich A, Menten B, Sante T, Smet J, Regal L, Lorber A, Khoury A, Zeviani M, Strom TM, Meitinger T, Bertini ES, Van Coster R, Klopstock T, Rotig A, Haack TB, Minczuk M, Prokisch H. Mutations in GTPBP3 Cause a Mitochondrial Translation Defect Associated with Hypertrophic Cardiomyopathy, Lactic Acidosis, and Encephalopathy.

American Journal of Human Genetics. 2014;95(6):708-20.

7. Kamon M, Katano M, Hiraki-Kamon K, Hishida T, Nakachi Y, Mizuno Y, Okazaki Y, Suzuki A, Hirasaki M, Ueda A, Nishimoto M, Kato H, Okuda A. Identification of Ccr4-not complex components as regulators of transition from partial to genuine induced pluripotent stem cells. *Stem Cells and Development*. 2014;23(18):2170-9.
8. Hishida T, Nakachi Y, Mizuno Y, Katano M, Okazaki Y, Ema M, Takahashi S, Hirasaki M, Suzuki A, Ueda A, Nishimoto M, Hishida-Nozaki Y, Vazquez-Ferrer E, Sancho-Martinez I, Izpisua Belmonte JC, Okuda A. Functional compensation between Myc and PI3K signaling supports self-renewal of embryonic stem cells. *Stem Cells*. 2014.
9. Enoki Y, Sato T, Tanaka S, Iwata T, Usui M, Takeda S, Kokabu S, Matsumoto M, Okubo M, Nakashima K, Yamato M, Okano T, Fukuda T, Chida D, Imai Y, Yasuda H, Nishihara T, Akita M, Oda H, Okazaki Y, Suda T, Yoda T. Netrin-4 derived from murine vascular endothelial cells inhibits osteoclast differentiation in vitro and prevents bone loss in vivo. *FEBS Letters*. 2014;588(14):2262-9.
10. Awata T, Yamashita H, Kurihara S, Morita-Ohkubo T, Miyashita Y, Katayama S, Mori K, Yoneya S, Kohda M, Okazaki Y, Maruyama T, Shimada A, Yasuda K, Nishida N, Tokunaga K, Koike A. A genome-wide association study for diabetic retinopathy in a Japanese population: potential association with a long intergenic non-coding RNA. *PloS One*. 2014;9(11):e111715.
11. Yamashita-Sugahara Y, Tokuzawa Y, Nakachi Y, Kanasaki-Yatsuka Y, Matsumoto M, Mizuno Y, Okazaki Y. Fam57b (family with sequence similarity 57, member B), a novel peroxisome proliferator-activated receptor gamma target gene that regulates adipogenesis through ceramide synthesis. *The Journal of Biological Chemistry*. 2013;288(7):4522-37.
12. Mizuno Y, Ninomiya Y, Nakachi Y, Iseki M, Iwasa H, Akita M, Tsukui T, Shimozawa N, Ito C, Toshimori K, Nishimukai M, Hara H, Maeba R, Okazaki T, Alodaib AN, Al Amoudi M, Jacob M, Alkuraya FS, Horai Y, Watanabe M, Motegi H, Wakana S, Noda T, Kurochkin IV, Mizuno Y, Schonbach C, Okazaki Y. Tysnd1 deficiency in mice interferes with the peroxisomal localization of PTS2 enzymes, causing lipid metabolic abnormalities and male infertility. *PLoS Genetics*. 2013;9(2):e1003286.
13. Kazuno AA, Ohtawa K, Otsuki K, Usui M, Sugawara H, Okazaki Y, Kato T. Proteomic analysis of lymphoblastoid cells derived from monozygotic twins discordant for bipolar disorder: a preliminary study. *PloS One*. 2013;8(2):e53855.
14. Iseki H, Takeda A, Andoh T, Kuwabara K, Takahashi N, Kurochkin IV, Ishida H, Okazaki Y, Koyama I. ALEX1 suppresses colony formation ability of human colorectal carcinoma cell lines. *Cancer Sci*. 2012;103(7):1267-71.

前門戸任（研究分担者）

1. Watanuki Z, Kosai H, Osanai N, Ogama N, Mochizuki M, Tamai K, Yamaguchi K, Satoh K, Fukuhara T, Maemondo M, Ichinose M, Nukiwa T, Tanaka N. Synergistic cytotoxicity of afatinib and cetuximab against EGFR T790M involves Rab11-dependent EGFR recycling. *Biochemical and Biophysical Research Communications*. 2014;455(3-4):269-76.

2. Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma A, Hagiwara K, Kobayashi K. Effectiveness of Gefitinib against Non-Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2014;9(2):189-94.
3. Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. *The Lancet Oncology*. 2014;15(11):1236-44.
4. Nihira K, Miki Y, Iida S, Narumi S, Ono K, Iwabuchi E, Ise K, Mori K, Saito M, Ebina M, Sato I, Maemondo M, Yamada-Okabe H, Kondo T, Sasano H. An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma. *The Journal of pathology*. 2014;234(2):277-88.
5. Morita M, Fukuhara T, Takahashi H, Maemondo M. Small cell lung cancer and progressive retinopathy. *BMJ Case Reports*. 2014;2014.
6. Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study G. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903). *Lung Cancer*. 2014;86(2):195-200.
7. Maemondo M, Inoue A, Sugawara S, Harada T, Minegishi Y, Usui K, Miwa K, Morikawa N, Kambe M, Ube K, Watanabe K, Ishimoto O, Sakakibara T, Gemma A, Nukiwa T. Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801. *Oncologist*. 2014;19(4):352-3.
8. Kawashima Y, Inoue A, Sugawara S, Oizumi S, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802. *Respiratory Investigation*. 2014;52(3):190-4.
9. Inoue A, Sugawara S, Harada M, Kobayashi K, Kozuki T, Kuyama S, Maemondo M, Asahina H, Hisamoto A, Nakagawa T, Hotta K, Nukiwa T. Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2014;9(12):1805-9.
10. Sugawara S, Maemondo M, Tachihara M, Inoue A, Ishimoto O, Sakakibara T, Usui K, Watanabe H, Matsubara N, Watanabe K, Kanazawa K, Ishida T, Saijo Y, Nukiwa T, North Japan Lung Cancer Study G. Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer:

NJLCC 0601. Lung Cancer. 2013;81(1):91-6.

11. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, Ohe Y, Nogami N, Takeuchi K, Shimada T, Tanaka T, Tamura T. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. *The Lancet Oncology*. 2013;14(7):590-8.
12. Seki T, Nishino Y, Tanji F, Maemondo M, Takahashi S, Sato I, Kawai M, Minami Y. Cigarette smoking and lung cancer risk according to histologic type in Japanese men and women. *Cancer Sci*. 2013;104(11):1515-22.
13. Matsubara N, Maemondo M, Inoue A, Ishimoto O, Watanabe K, Sakakibara T, Fukuhara T, Morikawa N, Tanaka M, Sugawara S, Nukiwa T. Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCC0703. *Respiratory Investigation*. 2013;51(1):28-34.
14. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). *Ann Oncol*. 2013;24(1):54-9.
15. Harada T, Oizumi S, Ito K, Takamura K, Kikuchi E, Kuda T, Sugawara S, Suzuki A, Maemondo M, Fujita Y, Kinoshita I, Inoue A, Hommura F, Katsuura Y, Dosaka-Akita H, Isobe H, Nishimura M, Hokkaido Lung Cancer Clinical Study G. A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901. *Oncologist*. 2013;18(4):439-45.
16. Goto K, Nishio M, Yamamoto N, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Fukuyama T, Tamura T. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). *Lung Cancer*. 2013;82(1):109-14.
17. Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, Fujita Y, Gemma A, Yamashita Y, Ueno T, Takeuchi K, Choi YL, Miyazawa H, Tanaka T, Hagiwara K, Mano H. A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non-Small Cell Lung Cancer. *Clin Cancer Res*. 2012;18(20):5682-9.
18. Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial. *Oncologist*. 2012;17(6):863-70.
19. Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, Gemma A. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. *Journal of thoracic oncology* : official publication of the International Association for the Study of Lung

Cancer. 2012;7(9):1417-22.

20. Kobayashi M, Miki Y, Ebina M, Abe K, Mori K, Narumi S, Suzuki T, Sato I, Maemondo M, Endo C, Inoue A, Kumamoto H, Kondo T, Yamada-Okabe H, Nukiwa T, Sasano H. Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma. *British Journal of Cancer*. 2012;107(10):1745-53.

吉澤 弘久 (研究分担者)

1. Yoshizawa K, Mukai HY, Miyazawa M, Miyao M, Ogawa Y, Ohyashiki K, Katoh T, Kusumoto M, Gemma A, Sakai F, Sugiyama Y, Hatake K, Fukuda Y, Kudoh S. Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization. *Cancer Sci*. 2014;105(2):195-201.
2. Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma A, Hagiwara K, Kobayashi K. Effectiveness of Gefitinib against Non-Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2014;9(2):189-94.
3. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). *Ann Oncol*. 2013;24(1):54-9.
4. Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial. *Oncologist*. 2012;17(6):863-70.

大泉 聡史 (研究分担者)

1. Iijima Y, Seike M, Noro R, Ibi T, Takeuchi S, Mikami I, Koizumi K, Usuda J, Gemma A. Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma. *International Journal of Oncology*. 2015;46(2):505-12.
2. Yokouchi H, Kanazawa K, Ishida T, Oizumi S, Shinagawa N, Sukoh N, Harada M, Ogura S, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M. Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review. *Molecular and Clinical Oncology*. 2014;2(5):744-50.
3. Okamoto I, Sakai K, Morita S, Yoshioka H, Kaneda H, Takeda K, Hirashima T, Kogure Y, Kimura T, Takahashi T, Atagi S, Seto T, Sawa T, Yamamoto M, Satouchi M, Okuno M, Nagase S, Takayama K, Tomii K, Maeda T, Oizumi S, Fujii S, Akashi Y, Nishino K, Ebi N, Nakagawa K, Nakanishi Y, Nishio K. Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. *Oncotarget*. 2014;5(8):2293-304.

4. Mizugaki H, Sakakibara-Konishi J, Kikuchi J, Moriya J, Hatanaka KC, Kikuchi E, Kinoshita I, Oizumi S, Dosaka-Akita H, Matsuno Y, Nishimura M. CD133 expression: a potential prognostic marker for non-small cell lung cancers. *International Journal of Clinical Oncology*. 2014;19(2):254-9.
5. Kawashima Y, Inoue A, Sugawara S, Oizumi S, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802. *Respiratory Investigation*. 2014;52(3):190-4.
6. Kanazawa K, Yokouchi H, Wang X, Ishida T, Fujita Y, Fujiuchi S, Harada T, Harada M, Takamura K, Oizumi S, Kinoshita I, Katsuura Y, Honjo O, Kojima T, Dosaka-Akita H, Isobe H, Munakata M, Nishimura M, Hokkaido Lung Cancer Clinical Study G. Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902. *Cancer Chemotherapy and Pharmacology*. 2014;74(6):1149-57.
7. Jinushi T, Shibayama Y, Kinoshita I, Oizumi S, Jinushi M, Aota T, Takahashi T, Horita S, Dosaka-Akita H, Iseki K. Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. *Cancer medicine*. 2014.
8. Ikezawa Y, Sukoh N, Shinagawa N, Nakano K, Oizumi S, Nishimura M. Endobronchial ultrasonography with a guide sheath for pure or mixed ground-glass opacity lesions. *Respiration; international review of thoracic diseases*. 2014;88(2):137-43.
9. Inoue T, Katoh N, Onimaru R, Shimizu S, Tsuchiya K, Suzuki R, Sakakibara-Konishi J, Shinagawa N, Oizumi S, Shirato H. Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer. *Radiation oncology*. 2013;8:69.
10. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). *Ann Oncol*. 2013;24(1):54-9.
11. Harada T, Oizumi S, Ito K, Takamura K, Kikuchi E, Kuda T, Sugawara S, Suzuki A, Maemondo M, Fujita Y, Kinoshita I, Inoue A, Hommura F, Katsuura Y, Dosaka-Akita H, Isobe H, Nishimura M, Hokkaido Lung Cancer Clinical Study G. A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901. *Oncologist*. 2013;18(4):439-45.
12. Asano F, Shinagawa N, Ishida T, Shindoh J, Anzai M, Tsuzuku A, Oizumi S, Morita S. Virtual bronchoscopic navigation combined with ultrathin bronchoscopy. A randomized clinical trial. *American journal of respiratory and critical care medicine*. 2013;188(3):327-33.
13. Yamada N, Oizumi S, Asahina H, Shinagawa N, Kikuchi E, Kikuchi J, Sakakibara-Konishi J, Tanaka T,

Kobayashi K, Hagiwara K, Nishimura M. The Peptide nucleic Acid-locked nucleic Acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations in bronchoscopic cytological specimens of non-small cell lung cancer. *Oncology*. 2012;82(6):341-6.

14. Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, Fujita Y, Gemma A, Yamashita Y, Ueno T, Takeuchi K, Choi YL, Miyazawa H, Tanaka T, Hagiwara K, Mano H. A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non-Small Cell Lung Cancer. *Clin Cancer Res*. 2012;18(20):5682-9.
15. Sakakibara-Konishi J, Oizumi S, Kikuchi J, Kikuchi E, Mizugaki H, Kinoshita I, Dosaka-Akita H, Nishimura M. Expression of Bim, Noxa, and Puma in non-small cell lung cancer. *BMC Cancer*. 2012;12:286.
16. Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial. *Oncologist*. 2012;17(6):863-70.
17. Mizugaki H, Sakakibara-Konishi J, Ikezawa Y, Kikuchi J, Kikuchi E, Oizumi S, Dang TP, Nishimura M. gamma-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer. *British Journal of Cancer*. 2012;106(12):1953-9.
18. Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, Gemma A. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2012;7(9):1417-22.
19. Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Marquez VE, Nishimura M, Dosaka-Akita H. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. *Lung cancer*. 2012;78(2):138-43.
20. K K, Sakuyama T, Koizumi W, Sato A, Konishi H, Shimizu A, Fujimori M, Noro R, Kotajima F, Kudoh S, Kurihara M. Biweekly administration of irinotecan (CPT-11) plus cisplatin with an antidiarrheal program of intestinal alkalization to reduce diarrhea in cancer patients. *Ann Cancer Res*. 2012;20(2):52-7.

鈴木 朋子 (研究分担者)

1. Kawashima Y, Inoue A, Sugawara S, Oizumi S, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802. *Respiratory Investigation*. 2014;52(3):190-4.
2. Kawashima A, Suzuki T, Nishihara F, Kobayashi T, Takaku Y, Nakagome K, Soma T, Hagiwara K, Kanazawa M, Nagata M. Effect of formoterol on eosinophil trans-basement membrane migration induced by interleukin-8-stimulated neutrophils. *International Archives of Allergy and Immunology*. 2013;161 Suppl 2:10-5.